Business Description
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Business History
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -13.56
Total Equity: $1.33B
Shares: 89,032,613
Total Debt: $1.97B
Cash: $2.47B
EBITDA: -$1.10B
Total Debt: $1.97B
Cash: $2.47B
Revenue: $558.48M
Shares: 89,032,613
Revenue: $558.48M
Revenue: $558.48M
Revenue: $558.48M
Total Equity: $1.33B
Tax Rate: -0.6%
Equity: $1.33B
Total Debt: $1.97B
Cash: $2.47B
Current Liabilities: $1.64B
Long-Term Debt: $742.80M
Total Debt: $1.97B
Total Equity: $1.33B
Shares: 89,032,613
Shares: 89,032,613
CapEx: -$27.57M
Shares: 89,032,613
Stock Price: $16.77
Net Income: -$1.21B
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $27.9M | $209.7M | $222.0M | $980.7M | $558.5M |
| Cost of Revenue | $3.3M | $22.0M | $30.5M | $29.1M | $131.7M |
| Gross Profit | $24.6M | $187.7M | $191.4M | $951.6M | $426.7M |
| Operating Expenses | $957.8M | $1.0B | $1.1B | $1.3B | $1.6B |
| Operating Income | -$869.8M | -$849.8M | -$872.6M | -$369.7M | -$1.2B |
| Net Income | -$782.4M | -$882.9M | -$925.6M | -$405.4M | -$1.2B |
| EBITDA | -$798.3M | -$787.0M | -$743.6M | -$237.6M | -$1.1B |
| EPS | $-49.12 | $-53.60 | $-52.48 | $-5.36 | $-13.56 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.7B | $1.5B | $1.1B | $1.2B | $2.5B |
| Total Current Assets | $1.9B | $1.6B | $1.3B | $1.5B | $2.9B |
| Total Assets | $2.9B | $2.8B | $2.5B | $2.6B | $4.0B |
| Current Liabilities | $361.1M | $881.2M | $934.2M | $1.2B | $1.6B |
| Long-Term Debt | $1.0B | $1.3B | $1.2B | $868.6M | $742.8M |
| Total Liabilities | $1.7B | $2.4B | $2.4B | $2.3B | $2.6B |
| Total Equity | $1.2B | $408.7M | $60.4M | $264.2M | $1.3B |
| Retained Earnings | -$3.6B | -$4.4B | -$5.4B | -$5.8B | $0 |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$604.7M | -$653.9M | -$726.1M | -$111.4M | -$1.2B |
| Capital Expenditure | -$436.6M | -$237.0M | -$56.8M | -$24.3M | -$27.6M |
| Free Cash Flow | -$1.0B | -$890.9M | -$782.9M | -$135.6M | -$1.2B |
| Acquisitions (net) | -$36.2M | -$20.0M | -$20.0M | -$25.5M | -$43.3M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$25.9M | -$26.8M | -$5.9M | $0 | -$9.0M |
| Net Change in Cash | $686.9M | -$361.2M | -$307.6M | -$144.9M | $302.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 9:51pm (11h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.6B $809.5M – $3.0B
|
$2.4B $1.4B – $4.2B
|
$3.0B $1.8B – $5.4B
|
$5.2B $3.2B – $9.4B
|
| EBITDA |
-$1.3B -$2.5B – -$686.8M
|
-$2.0B -$3.6B – -$1.2B
|
-$2.5B -$4.6B – -$1.6B
|
-$4.4B -$7.9B – -$2.7B
|
| Net Income |
-$240.2M -$1.2B – $640.6M
|
-$141.8M -$287.6M – -$70.2M
|
-$372.4M -$755.0M – -$184.2M
|
$417.1M $206.4M – $845.7M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +651.4% | +5.9% | +341.8% | -43.1% |
| Gross Profit Growth | +663.6% | +2.0% | +397.1% | -55.2% |
| Operating Income Growth | +2.3% | -2.7% | +57.6% | -218.9% |
| Net Income Growth | -12.8% | -4.8% | +56.2% | -198.2% |
| EBITDA Growth | +1.4% | +5.5% | +68.0% | -360.8% |
Narrative Economics
market-narrative step).